Cost-effectiveness of care for patients with type 2 diabetes, an evaluation of an innovative shared diabetes care model.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON24530

Enrollment

1200

Registered

2006-12-08

Start date

2007-03-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus type 2

Interventions

Intervention I: A shared care model will be implemented in Amstelland in cooperation with the organisations involved with local diabetes care: VUmc, Amsterdam Homecare Organisation, Amsterdam doctors

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with type 2 diabetes; 2. Age 40-75 years; 3. Written informed consent; 4. Capable to fill in questionnaires; 5. Understanding of Dutch language.

Exclusion criteria

Exclusion criteria: Patients will be excluded for participation in this study if no beneficial effects can be expected in favour of the patient, according to the opinion of the GP.

Design outcomes

Primary

Measure	Time frame
1. The risk of developing coronary heart disease (using the UKPDS risk engine at baseline, 2 yrs before and year 1 and 2 after baseline); 2. All direct and indirect costs (cost diary); 3. Costs per lifeyear gained.	—

Secondary

Measure	Time frame
1. Absolute levels of fasting glucose; 2. HbA1c level; 3. Blood pressure; 4. Cholesterol; 5. Percentages adequately controlled patients (in accordance with the NHG standards); 6. Diabetes specific and generic quality of life; 7. Patient satisfaction; 8. Quality of life; 9. Quality of care as experienced by the patient; Percentage of patients that received all 3-monthly check-ups, a complete annual check-up, were hospitalized; 10. Total mortality measured by life expectancy; 11. Total morbidity measured by morbidity-free life expectancy and the net present value (NPV) of the number of life years gained; 12. QALY’s gained for the intervention scenario compared to the current practice scenario; 13.The NPV of total intervention costs; 14. The NPV of total costs of care for diabetes and its complications; 15. Incremental costs per QALY gained.	—

Measure

Time frame

1. Absolute levels of fasting glucose; 2. HbA1c level; 3. Blood pressure; 4. Cholesterol; 5. Percentages adequately controlled patients (in accordance with the NHG standards); 6. Diabetes specific and generic quality of life; 7. Patient satisfaction; 8. Quality of life; 9. Quality of care as experienced by the patient; Percentage of patients that received all 3-monthly check-ups, a complete annual check-up, were hospitalized; 10. Total mortality measured by life expectancy; 11. Total morbidity measured by morbidity-free life expectancy and the net present value (NPV) of the number of life years gained; 12. QALY’s gained for the intervention scenario compared to the current practice scenario; 13.The NPV of total intervention costs; 14. The NPV of total costs of care for diabetes and its complications; 15. Incremental costs per QALY gained.

—

Contacts

Public ContactA. Heijden, van der

Emgo-Instituut Van der Boechorststraat 7

A.vanderHeijden@vumc.nl+31 20-4448409

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)